APRE News and Press, Aprea Therapeutics Inc. From 02/22/23

Aprea Therapeutics ( NASDAQ: APRE ) said Wednesday it has commenced an underwritten public offering of shares of its common stock. All shares of common stock in the offering are to be sold by Aprea. Aprea also intends to grant the underwriter in the offering a 30-day optio...

DOYLESTOWN, Pa., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, t...

DOYLESTOWN, Pa., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced that it received an award notificati...

Aprea Therapeutics ( NASDAQ: APRE ) announced a one-for-twenty reverse stock split which became effective on February 10, 2023. The company’s stock will trade on the Nasdaq on a split-adjusted basis beginning on February 13, 2023, under the company’s existing trading...

DOYLESTOWN, Pa., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (the “Company”), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced a one-...

Aprea Therapeutics ( NASDAQ: APRE ) has announced the appointment of John Hamill as Chief Financial Officer. Mr. Hamill joins Aprea with more than 30 years of finance and accounting experience. The Company also announced that Scott Coiante will be stepping down as Ch...

DOYLESTOWN, Pa., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced the appointment of John Hamill as Ch...

DOYLESTOWN, Pa., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced that it will participate in the 6 ...

A Boston-based %Biotech company is turning heads on Wednesday after the company announced that the first patient was dosed in its Phase 1/2a monotherapy clinical trial of ATRN-119, the Company’s lead ATR inhibitor for the treatment of cancers with DDR mutations, according to the releas...

Penny Stocks To Watch: January 2023 Edition This week has already been wild, and we aren’t even halfway there yet. Despite what broader markets have done, penny stocks continue performing for traders. The unique makeup of these cheap stocks tends to see company-specific speculation...